Compare Hershey Co (HSY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Tango Therapeutics Inc. — how do they compare? Hershey Co trades at $165.42 (market cap $32.76B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Hershey Co is far larger — about 8.7× Tango Therapeutics Inc.'s market cap, and Hershey Co pays a 3.56% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Tango Therapeutics Inc. for 0 Days on average.
| HSY | TNGX | |
|---|---|---|
Market Cap | $32.76B | $3.75B |
Volume | 1,118,576 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $32.90 |
52-Week Low | $157.61 | $7.50 |
Typical Hold Time | 135 Days | 0 Days |
Enterprise Value | $37.89B | $2.77B |
Dividend Yield | 3.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSY trades at $164.25, up 0.25% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 38.38% gross margins and 32.81% ROE, though 2025 net income declined to $883M. Analyst consensus is mixed with 68.57% hold ratings but a $203.69 price target suggesting 24% upside. Recent news highlights dividend resumption and international leadership changes.
HSY presents a value opportunity with reasonable valuation multiples (P/E 22.27) and dividend yield, but faces headwinds from cocoa cost pressures and technical weakness. The stock's investment case hinges on margin recovery and successful execution of brand investments amid competitive consumer staples landscape.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
